Carl Zeiss boosts digital solutions with cloud-based cataract surgery planning tool

cloud
Carl Zeiss added Veracity Innovations' cloud-based tool for cataract surgical planning, management and analysis to its digital solutions stable.

Carl Zeiss Meditec announced its acquisition of Veracity Innovations and its cloud-based platform that provides physicians with quick and easy access to clinical data at each stage of patient care.

The Veracity platform debuted at the American Society of Cataract and Refractive Surgery’s annual meeting. It connects with electronic medical records and diagnostic devices to supply doctors with “the most relevant and critical data” that they need at each step of treatment, from the initial consultation through the planning, scheduling, procedural and postoperative process, according to a statement.

The technology aims to make this process more efficient, while also cutting down on human error, Zeiss said in the statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Philips, Salesforce.com to create clinical, cloud-based platform

"Digital technology is fundamentally changing our world and has a major impact in healthcare," said CEO Ludwin Monz. "Efficiently bringing together relevant information and making smart use of data in a secure way, along with artificial intelligence, is reshaping how medicine is practiced today and is opening up new realms of possibility for advancing patient care."

Zeiss already offers a number of digital solutions for eye doctors, such as tools for decision support and data management, said Jim Mazzo, global president of ophthalmic devices at Zeiss.

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.